vs
Side-by-side financial comparison of FENNEC PHARMACEUTICALS INC. (FENC) and PATRIOT NATIONAL BANCORP INC (PNBK). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $9.5M, roughly 1.4× PATRIOT NATIONAL BANCORP INC). On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 44.3%). Over the past eight quarters, PATRIOT NATIONAL BANCORP INC's revenue compounded faster (11.5% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
FENC vs PNBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $9.5M |
| Net Profit | $-4.8M | — |
| Gross Margin | — | — |
| Operating Margin | -18.5% | -36.3% |
| Net Margin | -34.7% | — |
| Revenue YoY | 73.8% | 44.3% |
| Net Profit YoY | -141.1% | — |
| EPS (diluted) | $-0.17 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $9.5M | ||
| Q3 25 | $12.5M | $7.2M | ||
| Q2 25 | $9.7M | $6.2M | ||
| Q1 25 | $8.8M | $6.7M | ||
| Q4 24 | $7.9M | $6.6M | ||
| Q3 24 | $7.0M | $7.1M | ||
| Q2 24 | $7.3M | $7.1M | ||
| Q1 24 | $25.4M | $7.7M |
| Q4 25 | $-4.8M | — | ||
| Q3 25 | $-638.0K | $-2.7M | ||
| Q2 25 | $-3.2M | $-5.0M | ||
| Q1 25 | $-1.2M | $-2.8M | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-5.7M | $-27.0M | ||
| Q2 24 | $-5.6M | $-3.1M | ||
| Q1 24 | $12.8M | $-299.0K |
| Q4 25 | -18.5% | -36.3% | ||
| Q3 25 | -1.5% | -36.9% | ||
| Q2 25 | -28.3% | -81.2% | ||
| Q1 25 | -9.2% | -41.5% | ||
| Q4 24 | -11.8% | -205.4% | ||
| Q3 24 | -74.6% | -32.4% | ||
| Q2 24 | -69.4% | -56.5% | ||
| Q1 24 | 54.2% | -3.0% |
| Q4 25 | -34.7% | — | ||
| Q3 25 | -5.1% | -36.8% | ||
| Q2 25 | -32.7% | -80.4% | ||
| Q1 25 | -13.3% | -41.6% | ||
| Q4 24 | -25.0% | — | ||
| Q3 24 | -82.2% | -378.9% | ||
| Q2 24 | -76.5% | -43.5% | ||
| Q1 24 | 50.6% | -3.9% |
| Q4 25 | $-0.17 | $0.13 | ||
| Q3 25 | $-0.02 | $-0.03 | ||
| Q2 25 | $-0.11 | $-0.06 | ||
| Q1 25 | $-0.04 | $-0.21 | ||
| Q4 24 | $-0.02 | $-2.40 | ||
| Q3 24 | $-0.21 | $-6.78 | ||
| Q2 24 | $-0.20 | $-0.77 | ||
| Q1 24 | $0.41 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $36.8M | — |
| Total DebtLower is stronger | — | $16.4M |
| Stockholders' EquityBook value | $35.5M | $94.7M |
| Total Assets | $70.6M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $36.8M | — | ||
| Q3 25 | $21.9M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $22.7M | — | ||
| Q4 24 | $26.6M | — | ||
| Q3 24 | $40.3M | — | ||
| Q2 24 | $43.1M | — | ||
| Q1 24 | $51.2M | — |
| Q4 25 | — | $16.4M | ||
| Q3 25 | $19.4M | — | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $19.4M | — | ||
| Q4 24 | $19.3M | $33.1M | ||
| Q3 24 | $32.1M | — | ||
| Q2 24 | $31.8M | — | ||
| Q1 24 | $31.3M | — |
| Q4 25 | $35.5M | $94.7M | ||
| Q3 25 | $-4.5M | $95.0M | ||
| Q2 25 | $-7.5M | $66.2M | ||
| Q1 25 | $-5.9M | $57.1M | ||
| Q4 24 | $-5.9M | $4.3M | ||
| Q3 24 | $-5.2M | $16.4M | ||
| Q2 24 | $-1.4M | $40.5M | ||
| Q1 24 | $3.0M | $43.6M |
| Q4 25 | $70.6M | $1.1B | ||
| Q3 25 | $49.3M | $950.8M | ||
| Q2 25 | $44.9M | $930.0M | ||
| Q1 25 | $46.4M | $956.6M | ||
| Q4 24 | $44.9M | $1.0B | ||
| Q3 24 | $58.9M | $974.1M | ||
| Q2 24 | $63.2M | $1.0B | ||
| Q1 24 | $69.2M | $1.1B |
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.76× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 10.40× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-14.2M |
| Free Cash FlowOCF − Capex | — | $-14.3M |
| FCF MarginFCF / Revenue | — | -150.8% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-24.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $-14.2M | ||
| Q3 25 | $1.5M | $-5.2M | ||
| Q2 25 | $-3.7M | $921.0K | ||
| Q1 25 | $-4.3M | $-5.8M | ||
| Q4 24 | $-1.5M | $2.7M | ||
| Q3 24 | $-2.2M | $-2.6M | ||
| Q2 24 | $-8.4M | $6.0M | ||
| Q1 24 | $39.0M | $1.8M |
| Q4 25 | — | $-14.3M | ||
| Q3 25 | — | $-5.3M | ||
| Q2 25 | — | $918.0K | ||
| Q1 25 | — | $-5.9M | ||
| Q4 24 | — | $2.6M | ||
| Q3 24 | — | $-2.7M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $1.8M |
| Q4 25 | — | -150.8% | ||
| Q3 25 | — | -72.8% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | -88.0% | ||
| Q4 24 | — | 39.9% | ||
| Q3 24 | — | -37.3% | ||
| Q2 24 | — | 84.6% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.04× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
